Preventive effect of levodopa on vitiligo development: a nationwide case-control study
Br J Dermatol
.
2022 Aug;187(2):259-261.
doi: 10.1111/bjd.21054.
Epub 2022 May 13.
Authors
Jung Min Bae
1
,
Miri Kim
2
,
Ju Hee Han
3
,
Solam Lee
4
,
Hyun Jeong Ju
1
,
Jee Woo Kim
5
,
Abdurrahman Almurayshid
6
,
Chong Won Choi
5
Affiliations
1
Department of Dermatology, St Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
2
Department of Dermatology, Yeouido St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
3
Department of Dermatology, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
4
Department of Preventive Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.
5
Department of Dermatology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
6
Department of Medicine, College of Medicine, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.
PMID:
35157304
DOI:
10.1111/bjd.21054
No abstract available
Publication types
Letter
MeSH terms
Case-Control Studies
Humans
Hypopigmentation*
Levodopa / therapeutic use
Risk Factors
Vitiligo* / drug therapy
Vitiligo* / prevention & control
Substances
Levodopa
Grants and funding
the Catholic Medical Center Research Foundation made in the program year of 2021